The oral TKI sevabertinib has been granted priority review for use in patients harboring HER2 mutations in non-small cell ...

Adding immunotherapy to chemo may boost pCR and downstaging rates in the neoadjuvant setting for muscle-invasive bladder ...

Panelists discuss the safety profile and adverse effects of elacestrant, highlighting its relatively mild nausea and ease of administration compared with other endocrine therapies.

Panelists discuss how balancing effective disease control with managing treatment-related adverse effects in patients with chronic myeloid leukemia (CML) requires a strategic approach that may ...

Panelists discuss the EMERALD trial data, which shows the effectiveness of elacestrant in patients with estrogen receptor 1 (ESR1) mutations, particularly those who were on first-line CDK 4/6 ...

SVR10 at week 12 with pacritinib was linked to longer overall survival in patients with myelofibrosis and thrombocytopenia.

An oncology nurse shares advice for avoiding exhaustion and soreness when administering subcutaneous injections.

The FDA has approved the VENTANA MET (SP44) RxDx Assay as a companion diagnostic to identify individuals with non–small cell lung cancer (NSCLC) and high c-Met protein overexpression who may be ...

Patients with HR-positive, HER2-negative metastatic breast cancer should be consistently tested for ESR1 mutations to inform next lines of therapy.

The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC ...

Selecting the right treatment path for a patient with an ESR1 mutation in metastatic breast cancer can help build trust.

Panelists discuss how innovative approaches to symptom monitoring incorporate multifaceted technology and team-based strategies, including electronic patient-reported outcome tools integrated with ...